GSK announces initial findings from real world COPD study

摘要

Initial results have been announced from the Salford Lung Study, a phase III clinical trial in which researchers sought to discover how a new combination treatment for chronic obstructive pulmonary disease (COPD) fared against traditional therapy in a real world setting. According to GlaxoSmithKline (GSK), which released the results on 24 May 2016, its Relvar Ellipta inhaler (100μg fluticasone furoate/25μg vilanterol [FF/VI]) achieved a superior reduction in exacerbations in COPD patients compared with their usual care.